 Good afternoon everyone. Welcome to this session on maturing immunization systems, linking learning from COVID-19 and routine immunization. In this session we will talk about real-time monitoring. And we have three interesting speakers with us in this session. We have, first out is Karin Gauhan from Gavi. She is senior manager in their digital health information department. She will talk about how Gavi's current outlook and priorities for information system support for immunization and how the COVID-19 pandemic has highlighted challenges and also seen highly relevant routine immunization priorities. We have Johannes Dugasa. He is a field epidemiologist from Ethiopia and he will present a project where they're introducing DHS2 to monitor vaccine preventable diseases in Ethiopia. And then last but not least, we have Dr. Moala Baksh Chaudhry. He is a program manager for EPI and member secretary of the COVID-19 vaccination deployment and preparedness core committee in Bangladesh. He will present their implementation story of DHS2 under measles and rubella campaign in terms of online microplanning, supervision and real-time monitoring, where they successfully vaccinated over 30 million children earlier this year. Very impressive feat. And I think we can say, as was also discussed in the previous session, that DHS2 has been expanded to cover many key needs in the immunization space in the past years, with over 50 plus countries using DHS2 for core functions in their vaccine programs. And the COVID-19 vaccine programs have been a key driver for rapid expansion and improvements to the platform. And they're also building on these routine immunization packages under the WHO metadata package framework. And really COVID-19 has put the spotlight on importance of real-time monitoring and data availability for action at the time that the data is most relevant. But of course, this isn't only relevant for COVID. It's highly relevant for all other immunization programs as well. So, in this session, I hope we can sort of illuminate this from different perspectives. A couple of practical information before we get started. Let me just change slides. You can ask questions to the presenters either here on the chat on Zoom and also we encourage you to continue the conversation in our community of practice. We will share the links to that in the chat. All these links are on the SCAD session and also here. And we would love for it to be interactive as well and open to questions. I think we will have time for that in the end. So with that, I will give the word to Corinne. Okay. Good afternoon. Good morning to everyone. I hope you can hear me and see me. Yes, it's okay. So I'm very happy to be here and really wanted to thank the University of Oslo and also his for organizing. I know the conference is really expected every year. So I'm happy to be here. I just want to share my screen and give few words. One second. Sorry. Is that big enough and everyone can see. Perfect. Okay. So, you know, Gaby is a global alliance for vaccination and immunization and we have been working with the University of Oslo, the bridge show and UNICEF and all the partners to work for immunization. And as you have seen, there's been also a lot of work on COVID-19. And now with COVID-19 vaccination specifically. So, just quickly, we will look on, you know, we will watch what was the achievement of the recent year and the collaboration together we will pass rapidly on what has happened for COVID-19 surveillance and vaccination and just few words on how we could look forward together. So, on the achievement, this is just a reference you are all now aware you can click on that link and go to the DHIS2.org immunization platform and you will see all the different packages so you will see everything that is available. And, you know, and to be used by all the countries and the partner to help strengthening the immunization program. In terms of results, we put here a few numbers and of course, you know, the results are way beyond just numbers but how countries are using the data, how they are using those data to improve the immunization. But obviously for the past two, three years now the immunization program are really making progress and in taking the best from DHIS2 is a lot of work so you can find, you know, some reference on all the updates of the different immunization related module and, you know, kind of an example of this achievement is that, you know, a couple of less than three years has been a lot of countries we have stopped their parallel system for immunization information system and have been integrated immunization system into the National Health Information System and DHIS2. So, in the countries that give you support, majority of the countries are fully integrated into DHIS2 for the immunization information system. Of course, countries can choose the system they want and we are not giving any preference but we are just, you know, seeing a clear uptake on the DHIS2 platform. For COVID-19, there's been several sessions, you have seen that just putting back again the link for the website where you can find all the information for both aspects, the surveillance to monitor how the epidemic is evolving and on the vaccination side because now COVID-19 has become a vaccine preventable disease so we have all the package for vaccination as well and you have seen the description of all those packages. And you know the uptake, the uptake on the surveillance module has been very rapid and is a kind of opening release a door for that new surveillance package that is now available on DHIS2 for vaccine preventable disease and integrated package and where COVID-19 fits as well. And now for the vaccination of against the COVID-19 disease, you have seen how the country are picking up and we hope that of course this will be merging and efforts will be done for supporting the integration into the routine immunization system. So just a few words, you have already one hour on all those, you know, new way of working and going. I just wanted to remind everyone what are the priority in the digital health information area for GAVI and our new strategy called the GAVI50, the strategy that is now started for five years and this is very important for us because clearly countries are using DHIS2 and DHIS2 is one of the core piece of the ecosystem around the information system for immunization. And one way or another is directly either with some module or with via interoperability, the DHIS2 has a role to play in all our six priorities, which are you know how to identify and reach the zero dose and immunize children. We have also a lot on how to empower district health manager and making sure you know they can access the data easily. As you have seen, we are going to see, sorry, how DHIS2 can support what we call the real time planning and monitoring of immunization campaigns, and also a lot of things is happening on the ELMIS side and how DHIS2 can facilitate, you know, the visibility of data from the CET level and have some interoperability with ELMIS, there will be a lot of session on that. And we have DHIS2, the track and the electronic immunization registries that help us of course on reducing the default, the one where not all the, sorry for that. And we have, sorry, it's just a proof that this is direct live, and then we have also the DHIS2 that can obviously help around the surveillance information system. And all of this in the GAVI with a new strategy is also linked with the innovation strategy and this link with our COVID-19 vaccine delivery strategy. There is a way forward, DHIS2 has space everywhere and we are really calling upon all of you to help innovating in DHIS2 to support all our priorities. The most important thing is that where we came together and we were very happy to have University of Oslo and DHIS organizing this session is that obviously the pandemic and the way to roll out worldwide campaign for a vaccine have showed us like very clear needs that are coming on a very acute way. You have seen the session on the adverse effect for the immunization, the link with VG base, and we have seen that it's a huge effort that is needed to give people confidence back into the vaccines and reassure them. And for that is having a re-transparent system reporting adverse effect for the immunization is really so important. And so for COVID-19, for other vaccines and a lot of vaccine are coming to the way of the country we support. And this piece is really important and national just set aside but become a core piece of information system and we have seen that DHIS2 has real role to play there. Another area and you talk about it I think already and this is going to continue is not just here to help country to report, of course we need to have country reporting at the global level and all of that but what is important is that countries have freely to take critical decision on how to run the vaccination, how to optimize the use of vaccine knowing that specialist vaccines that are set in a kind of emergency period. It's a very short expiry date so you really need to know where is your stop but in some time you also need to monitor rumors and monitor the needs and the demand for vaccine in some time and you need to make sure you have all you vaccination team ready to communicate at the right place with the vaccines. So you see that is an important volume of insights and not just data but insight that have to come together and need to be triangulated and need to be made available for decision maker in a kind of really real time basis. So this has been really critical for the first six months of the rollout of the vaccines and we see a lot of demand from the country telling us how can I have all those data you know in any way and I can triangulate those data and take decision. So, and we have some examples that are coming from countries using DHS to demonstrate that is also coming with a notion of real time planning and monitoring so this was really done and developed for the campaign, the vaccination campaign, also the LLN campaign, all the campaign. So if we see that for example for COVID-19 vaccination is a kind of campaign mode but on a very long duration. So we have new mechanism to be put in place we need to have reactive information system and DHS to can have that reactivity can absorb more data collection point more sites in one rule and also really play is for bringing information on real time manner. So a lot, a lot of learning from COVID-19 that we need to apply to routine immunization. And just my last point for countries who would like to be supported by Gavi for the DHS too. I just put that summary here, we have two kind of mechanism so for all what we call the country eligible to Gavi. This is on that call on you can really contact you send your country manager, you know how to work with Gavi, and there is contract grounds at any place between Gavi and the University of Oslo for technical assistance. And all the operational costs like if you need to organize training by equipment, internet connectivity, server cost and all of that. This is possible to support that via the HSS grant you have. And now, beyond routine immunization and the 57 Gavi eligible countries, we have also Gavi is part of the covax and Gavi can support what we call the AMC countries so it goes up to 92. So if those countries have specific needs related to COVID-19, the prevalence of the vaccination piece, and we have also a grant that is in place country can can ask for it. We live, this is for technical assistance and for operational costs. We have a new grant that is on the way coming called CDSS COVID-19 delivery system concerning what country can request some support for the DHS to be there. In any case always keep you Gavi senior country manager informed because the AMC country can also discuss with UNICEF with managing that piece. Always coordinate with WHO country office and regional office, and of course with your implementing partner, the ESP. And for country who are listening and want to use another system that can also ask for specific support to the SEM. And the last word will be really a big, big thank you for all the team. You are always been a very committed partners to Gavi to the countries beyond, you know, your usual commitment for routine immunization. We really saw what has been done for the COVID-19 pandemic as a surveillance and now the vaccination and really a big, big thank you for all the support. I'm ending over to you. Thank you so much Corinne for your continued support and positivity and really helping us moving this along. It's highly appreciated. Our next presenter is Johannes from Ethiopia. Are you ready? I will give the floor to you. Okay. Thank you very much, Annie and let me share my screen with participants. So, thank you very much, Annie for facilitation and I would like to appreciate the prior speaker just to give for giving us an oversight on what has been done from the Gavi side in enhancing the effective vaccination against COVID-19. Mine is just optimizing DHS to platform for vaccine preventable case-based reporting. Just we are trying to pave the way for the generation that will be used just to roll out or to expand the DHS to utilization for BPDs. Yeah, as you know that the public health surveillance is very, very necessary for each and every public health measure to be taken. Among that the effective mobilization is one of the public health measures that needs to be depend on the public health surveillance or it needs to be guided by the high quality data generated from the public health surveillance. For the routine immunization, we may not need the surveillance from the data from the surveillance but during the outbreak response or when we are undertaking reactive campaign or immunization against some specific diseases, we need to be highly guided by the evidence generator from the public health surveillance. We need to target specific age group, we need to target specific geographic area or just we need to select specific antigen for that disease. So all those information need to come from the public health surveillance and I can say that the public health surveillance is just a cornerstone or evidence for the effective immunization. So, just I will offer you some pointers on the current public health surveillance in Ethiopia. Just, I have already mentioned that public health surveillance is very, very crucial for every public health measures to be taken. Targeting one or more specific disease and in Ethiopia there is like 23 days or even to that have been included and there's a national surveillance system and as I have been selected based on different criteria. For those priority diseases, the measles, polio and the neonatal data are the primarily vaccine preventable diseases and just they are using the same route or channel with other diseases. So when we see data flow, the data came from the community health facility waradah zone region to the federal level. Just to contextualize waradah is to mean the district and region is the ones that correspond to Swiss provinces and the zone is intermediate admin structures that is found between the district and the province. So it flows such then just I'm talking about the vaccine preventable disease that we are under the national surveillance system and peculiarly those vaccine preventable disease are under the elimination or the eradication program for instance, the neonatal tenants and the measles were under the elimination and polio were under the eradication program and due to the inherent nature of those programs, there is huge demand for high quality data across every pillar of the responses. So, when we came to the surveillance procedure for vaccine preventable disease in Ethiopia. And I like that of most of the disease or event is under surveillance, those vaccine preventable disease depends on individual case by case reporting. So, once we encounter one vaccine preventable disease, we need to undertake individual case investigation and we need to fill detailed information on case based reporting format. And we need to feel just to, for instance, if we if one case is reported at catchment facilities down on the ground. After the investigations case based reporting format needs to be filled in five four to five copies and each copy should be delivered to the previous admin level that I mentioned like waradah zone region and the federal levels. That seems very tricky and tiresome for the health worker that is working it out on the ground. Then after feeling the case based reporting format there is sample collection and shipment to the referral laboratories and unfortunately the referral laboratories are either found at the regional level or at the national levels. And once as a sample was delivered to the laboratory and tested, there should be the result linkage so the reader that should be sent back to the site that initially reported the vaccine preventable disease and those all the staples need a standard period of time from my experience as I can take more than a week. And if the reported cases confirm it to be vaccine preventable disease. With this spread of times outbreak and propagate and leads to increase the number of cases days and the disabilities. So, when we came to the pitfall with the current vaccine preventable disease case based reporting. It is manual based. It is tiresome and amenable to ears. So, as I mentioned, each copy should be delivered to waradah zone region and the national levels and the most of the time from my experience. The copies are available at the facility level and at the federal level those intermediate levels don't have any copies reason. So, it is significant data quality gap in company data center discrepancies among the data, the data among different levels so the number of you get at the facility is different from the waradah from the waradah zone region and so on. There is longer durations than expected. Testing communicating result about to the sending sending the site takes longer so that we are allowing this outbreak to propagate without any intervention. So, if that happens, there is delay in the transition of response, increased case days and disabilities and ultimately there is a wastage of resource, financial human resource and specifically vaccine. There have been many first taken by the minister of health to tackle the issues with the data qualities and as a part of that, it will be a minister of health in collaboration with partner has customized the DHS to tracker to back up the aggregate data. So, that is targeting the aggregate data, the count is produced from the surveillance. That means this DHS tracker that doesn't accommodate individual case by case reporting of vaccine preventable use. The vaccine preventable needs sophisticated and the real time surveillance tool that gives away for strong monitoring and evaluation prospect and just we believe that DHS would be one of the tools that can at least pay the way for the strong monitoring and evaluation from work. So, this is a background with regard to the surveillance in countries and when we came to the initiation for this project, there is what we call gigs growing expertise in health and health knowledge and skills. And that was provided in Ethiopia, coordinated by ICAP and the CDC and this type of applied project based informatics training, targeting the health workers to help them use the DHS and other health information system. And this abstract or project that I'm presenting is ongoing a project that we're under implementation, primarily as a part of learning process for the trainees and the secondary just to optimize the DHS to platform for the vaccine preventable diseases. So, when we came to the objectives of this project, as I have already mentioned, it is an ongoing project that aims to optimize the DHS to platform for vaccine preventable diseases case based surveillance that we're primarily lacking in the current practice of the surveillance and just to generate quantifiable information for proper monitoring and evaluation prospectors. And specifically, the objective is to develop a comprehensive requirement to document we don't have a requirement to document to customize the DHS tracker for VPDs. So we are going to develop a requirement to document. We are going to customize the DHS to further develop the requirement to document, highlight and then ultimately producing genuine evidence for the Ministry of Health and other stakeholders that may be partner on operational feasibility of losing DHS to for vaccine preventable disease on in an umbrella just blanket approach. So, through the process we are following the first approach and the first phase is the desk review and analysis. We have already done the desk review and analysis on the relevant documents related to the DHS to implementation in Topia and we found out that there have been nothing done so far in utilizing the DHS to for the vaccine preventable disease and that seems very difficult to be done. It's very difficult because we are going to start from scratch. So we need to develop as a requirement to document to outline what type and specification of DHS to serve to be used for the vaccine preventable disease that may be very challenging but we are trying to implement that one. The second thing is customization of DHS track to DHS to tracker for VPDs. So once the requirement to document is in place and everyone agrees that this is the one to be used. We are going to customize DHS for the requirement to document. Then we are going to select the specific district or health facilities and we are going to pilot the development of DHS to track for vaccine preventable disease. Along that as a part of tracking the improvements just we are going to use key performance indicator specifically for surveillance to track whether the surveillance system is improving or not and just we are also going to support the health worker working at the selected or at the health facility and finally we are going to generate the evidence for full scale expansion. This is some sort of project and we cannot implement on as a part of the blanket coverage, but we are going to deliver some important evidences to roll out the DHS to tracker for VPD surveillance. Those are the major plan or on pipeline activities. Just as a baseline or the initiative is the Geeks training. It was given on December 12. Just after that there is a group formation from the Ministry of Health, Regional Health, Viruses and Partners and finally we selected the study project and we have developed the proposal developed and submitted to the IACAP Ethiopian as a mentors who are already assigned and subsequently we are going to develop a requirement to document the removal of the CLR workshop for customization in that every stakeholders will be part and a part of the task. Then there may be orientation document preparation and the test scenario development. There is testing after testing if we see something that need amendment we are going to make minor amendment to the DHS tracker. There is final pre-pilating final validation, implementation plan development and finally we are going to pilot on selected districts and other facilities. So as output outcome or in part of the project, primarily just as initially described as a training will have sufficient knowledge and the skill that will standardization of the public surveillance. Specifically, they will at least make themselves familiar on using DHS to for surveillance purposes. There may be well-designed requirement to document so that everybody who wants to expand this DHS may use as a source document for rolling out. There may be customized DHS to tracker. Then ultimately we are expecting to receive real time data from the selected reporting unit. Finally, just we are anticipating to have improved quality of data that is from the availability, completeness, timeliness, accuracy and from the consistency. Improved turnaround time for test suspected sample, improved data use for decision making and the prompt and timely response to outbreak are anticipated result from this project. So, in fact, this is an ongoing project and we need to work harder to achieve those anticipated outcome or project but we are striving to make it happen. This is all I have to talk. Thank you very much and over to you. Thank you very much. Thank you so much, Johannes, for your interesting presentation. I'm looking forward to following this project going forward. I will now give the word to Dr. Chaudhry in Bangladesh to talk about the immunization campaign that they have been managing. Over to you. The floor is yours. Thank you so much. You have about 20 minutes. Thank you. Can you see my slides? Perfect. Yeah, thank you. Good afternoon and good morning everybody. Before hand, I would like to express my heartfelt gratitude for inviting me as a speaker at this mysterious global platform. Through my presentation, I will try to provide you a brief idea about how Bangladesh has implemented online micro-planning and real-time monitoring during its successful MR campaign 2020 by using DHS2 despite of a plethora of challenges caused by ongoing COVID-19 pandemic. The current EPA system is using DHS2 in terms of case-based data capturing as well as aggregated data reporting. As part of case-based data capture, we are conducting whole-chain equipment tracking, implementing immunization e-tracking system alongside maintaining AFP, VPD, and AFI surveillance system. On the other hand, infant and woman immunization coverage report with vaccine and logistic management information system are being done as part of aggregated data reporting. This information system wing was established in Directorate General of Health Services under the Ministry of Health and Family Oil Fair in 2009. Since then, EPA has been using this platform extensively. In 2011, DHS2 implementation started up to district level. In 2013, routine EPA reporting implemented and in 2014, vaccine and logistic stock reporting in DHS2 initiated. In 2015, vaccine and logistic reporting implemented for whole country. In 2016, cold chain application in DHS2 implemented BLMIS implemented. In 2017, monitoring dashboard on EPA supply chain and cold chain system implemented. In 2019, VPD surveillance implemented immunization e-tracker initiated. Despite of a plethora of challenges caused especially by ongoing pandemic, we had to conduct the MR campaign 2020 to address a number of issues which are, Bangladesh conducted last MR catch-up campaign in 2014, in 2015, 85 to 95 of children received first dose and 80 to 85% received second dose of MR vaccine from 2016 to 2019. Surveillance data indicated measles incidence increased from 1.6 per million in 2015 to 29 per million in 2019. Similarly, number of lab confirmed measles are increased from 4 in 2015 to 82 in 2019. Due to COVID-19 pandemic situation, Bangladesh residual postponed MR from 12 December 2020 to 3 February 2021 with revised strategies. Before MR campaign 2020, we used to have paper-based micro-planning for both routine EPI and supplementary immunization activities. For monitoring purpose, we used to conduct in person visits to the campaign sites but this time we choose to use the pre-existing DHS2 online platform for micro-planning and real-time monitoring for following reasons. Governments mandated on sectorized digitalization ensure overall quality of the campaign, ensure equitable high coverage through close monitoring of achievement against target-based session. Fixing actual target as per micro-plan, continuous monitoring the quality of campaign and immediate action to rectify and improve. Find out MIS children and ensure vaccination of all MIS children through MOP-up session. Daily vaccine and logistic management plan and monitoring vaccine and logistic stock. Online micro-plan and real-time monitoring help to conduct quality campaign when physical monitoring options was very limited due to COVID-19 pandemic situation. Major partners, technical assistance and implementation, EPI, DHHS, GAVI, UNICEF, WHO. System development and server maintenance, MIS, DHHS, UNICEF, University of Oslo and DHHS2 community. Results behind reasons. Regions begin picking DHHS2 for real-time monitoring work. Since 2013, EPI is using DHHS2 for routine EPI reporting, vaccine and logistic management, and porch and equipment inventory. Well-trained personnel on use of DHHS2 at all level feel is our familiar with reporting using DHHS2. Organization unit required for MR campaign planning and reporting are already existing DHHS2. Plan to use the same platform of routine EPI micro-plan for MR campaign planning and reporting. As part of real-time monitoring, we did the following activities. First-line micro-plan, daily vaccination reporting including vaccine and logistic use, session supervision through Android app, house-to-house visit by first-line supervisor through Android app and rapid convenient monitoring, RCM that is RCM by second-line supervisor through Android apps. As I have mentioned before that this campaign has proved to be a successful one. Now I would like to elaborate the achievement. You can see the, sorry, monitor daily coverage against the target at all level and provided feedback. Identified areas of these children and conducted mock-up sessions. Monitor and address session quality issues, identified issues and children for routine elimination. You can see the MR campaign dashboard in the slide. Results, children vaccinated, 36 million approximately, number of sessions supervised, 239,501, household visits conducted, 178,704, rapid convenience monitoring survey conducted, 19,603, missed children identified for routine doses, 119,581. On micro-plan data set include vaccination site and date, target children, vaccinator, supervisor, volunteer and porter, name and mobile number, total 402,679 micro-plan data set, rural, 331,128 and urban, 71,544 used. Number two, vaccine and logistic management, session-wise vaccine and logistic planning. Number three, vaccination report, daily coverage, vaccine and logistic used and waste days. Next, this time real-time decision-making and planning of corrective actions were possible and national level managers were able to observe the campaign status up to the lowest unit. Number four, supervision, observed quality and qualitative aspect by supervision apps, session observation, household visit apps, coverage and missed children, rapid convenience monitoring apps, quality, coverage, missed children and community governance. And we can observe these apps work both online and offline to cover hard to reach area and no network areas also. All national and sub-national managers use these Android apps for campaign supervision and monitoring. Daily analysis of supervision and monitoring data help local and national managers to ensure quality and coverage of the campaign. Obviously, all checklist and forms were paper-based, so no scope for real-time analysis and decision-making. You can see the picture here. So this is the picture of supervision apps. This is their slide for planning. This is their consultation for consensus building, ideas and agreement among EPI and MIS, tool development, field testing, training guidelines, finalized. Reporting form with expert from EPI, MIS, UNICEF and WHO. Training of all personnel on online micro-plan, GL, MIS, reporting, supervision and RCM at all level. This is a material video developed for training purpose, organized, re-sustaining on revised tools during rescheduled of campaign due to COVID-19. Lessons learned, existing technology DHS tool can be robust platform for strengthening national e-health and management information system. Government ownership and support from all sector and partners is key. This is a tool-friendly apps, comprehensive interactive training and motivation of the user can lead technology-based innovation without providing additional devices. DHS-200 apps can be used for large-scale implementation, dedicated technical team required for continuous troubleshooting, server and system maintenance. DHS real-time system supported intensive monitoring to achieve result despite pandemic. Challenges, next please. Challenges, capacity of some aged workers to use new technology, shortage of dedicated person for data entry at sub-national level, sub-national capacity to provide software and server-related support. Challenges, strong leadership and commitment from national level successfully introduced all six innovations like micro-plan, supervision apps, household monitoring apps, RCM, BLMIS apps and reporting system. Completed campaign maintenance quality and achieved a remarkable coverage of 104% despite of COVID-19 pandemic. Multistakeholder involvement, especially University of Oslo, DHS-2 community and MIS, DHS-2 and his Bangladesh also. An additional mis-children reached with vaccination, building confidence to introduce technology-based innovation. Before I ending to my presentation, I want to thanks University of Oslo, WHO, UNICEF and his Bangladesh also. Thank you so much. Thank you so much for your presentation, Dr. Chaudhry. I would like to give the floor, if there are any questions in the audience to any of these two projects. Any questions now? If not, then I will ask a question to the Bangladesh team. With your experience now on monitoring this campaign real-time. What kind of advice do you have to others wanting to do the same? Either for COVID vaccination campaigns that are happening right now, but also immunization campaigns for more routine immunization. Do you have advice to others? From the experience of MR campaign, there's a real-time monitoring and other things, so we can use this idea in the COVID-19 also. And we have a plan other than COVID-19, we have a plan to introduce this type of innovations in the routine immunization in Bangladesh. Other countries can also follow our experience, which we are doing in the MR campaign. And they can reach you on the COP, the community practice. You have a page there where people can post their questions. So those also watching this in a recording can also find the Bangladesh team here and also the Ethiopian projects that Johannes presented. So if there are no more questions or comments from our speakers, anything you would like to add before we close? No, then I think we will close this session and we will see you again tomorrow. Martin, are there any expert launches now? You can stop the recording perhaps. No, I didn't see any questions in the lunch.